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The gastrointestinal tract (GIT) is exposed to various environmental pollutants including metals, that
contaminate food and water which may have toxic effects on body. GIT has large amount of microbes
that live in symbiosis and help the host in different ways. The resident gut microflora have a significant
role to play in detoxification and elimination of the harmful metals from the body. Chromium is a
naturally occurring heavy metal found commonly in environment in trivalent (Cr III) and hexavalent
(Cr VI) forms. Cr (VI) compounds have been shown to be potent occupational carcinogens. The reduction
of Cr (VI) to Cr (III) results in the formation of reactive intermediates that together with oxidative
stress and oxidative tissue damage, and a cascade of cellular events including modulation of apoptosis
regulatory gene p53 contribute to the cytotoxicity, genotoxicity and carcinogenicity of Cr(VI)-containing
compounds. The data discussed here with reference to chromium show that gut microflora have a
marked capacity to cope with the increased load of ingested metals and may contribute significantly in
the protection against metal toxicity.
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The gastrointestinal tract (GIT) is exposed to different
environmental pollutants that contaminate food and water.
These include metals that may have toxic effects on
body. Many metals have no known biological function
and some of these are capable of disrupting essential
physiological processes. Examples include arsenic,
cadmium, lead, chromium and mercury. Some metals
also serve a chemically important role as essential
components of many enzymes. These metalloenzymes
are involved in the synthesis, repair and degradation of
biological molecules, release and recognition of certain
biological signaling molecules, and transfer of small
molecules and electrons in crucial processes such as in
respiration. For example, iron-containing haemoglobin
transports oxygen in blood. The toxic effects of most
metals can be traced due to their ability to disrupt the
function of essential biological molecules, such as proteins,
enzymes and DNA. In some cases this involves
displacing chemically related metal ions that are required
for important biological functions such as cell growth,
division and repair.
Certain heavy metals form very stable and long-lasting
complexes with sulphur in biological molecules, which
can disrupt their biological function. In some cases these
metals may be concentrated at higher levels of the food
chain. The body has developed various mechanisms to
detoxify the toxic substances, including the metals and
the cells and the secretions of GIT play an important
role in this process. The cells have evolved a complex
network of metal trafficking pathways. The object of
such pathways is to prevent accumulation of the metal
in the freely reactive form (metal detoxification
pathways) and to ensure proper delivery of the ion to
target metalloproteins (metal utilization pathways)1. In
recent times, microbes have been shown to reduce a
wide range of toxic metals viz., chromium [Cr(VI)],
mercury [Hg(II)], cobalt [Co(III)], lead [Pb(II)], and
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arsenic [As(V)]. Under certain conditions, microbial
metal reduction can mobilize toxic metals with potentially
calamitous effects on human health. Lloyd2 has discussed
the role of microbes in reducing different metals and its
impact on the environment. The resident gut microflora
may also have a significant role to play in detoxification
and elimination of the harmful metals from the body.
This review covers the existing knowledge on this aspect
with reference to chromium.
Gut microflora: A large number of bacteria belonging
to 300–500 different species live and grow in the
human intestine as symbionts3-4. Some common
resident bacteria found at different locations in the
GIT are listed in the Table. The stomach, duodenum
(0-104 bacteria/g of the luminal contents) and small
intestine (105-106 bacteria/g) contain smaller number
of bacteria adhering to the epithelia and some other
bacteria in transit. This may be because of the
composition of the luminal fluid containing acid, bile,
and pancreatic secretion, which kill most ingested
microorganisms. On the other hand, the large intestine
contains a complex and dynamic microbial population
with high densities of living bacteria. The luminal
contents may have up to 1011 or 1012 bacteria/g3 .
Some of these bacteria are potential pathogens and
can be a source of infection and sepsis under certain
conditions, for example when the integrity of the
bowel barrier is physically or functionally broken
down. A constant interaction between the host and
the microbes provide important health benefits to the
human host5.
Microorganisms start colonization of the
gastrointestinal tract soon after birth and this process
continues throughout the life. The environmental factors
have a major role in determining the extent and type of
colonization, for example, differences exist between
people living in developed countries and those in
developing countries6-7. Some bacteria can modulate
expression of genes in host epithelial cells8, thus creating
a favourable habitat for themselves, and can prevent
growth of other bacteria introduced later. The initial
colonization is therefore very relevant to the final
composition of the permanent flora in adults. It has been
shown3  that anaerobic bacteria outnumber aerobic
bacteria by a factor of 100–1000. The predominant
genera in human beings are Bacteroides,
Bifidobacterium, Eubacterium, Clostridium,
Peptococcus, Peptostreptococcus, and Ruminococcus
etc.3,5, followed by aerobes (facultative anaerobes) such
as Escherichia, Enterobacter, Enterococcus,
Klebsiella, Lactobacillus, Proteus etc. (Table). Every
individual has several hundreds of species, with a
particular combination that is distinct from that found in
other individuals. The species vary greatly between
individuals3,9.
Molecular biology techniques are being used to
investigate the microbial ecology in the gut without use
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Table. Common resident gut microflora
   Part of GIT Some common resident bacteria
Mouth and oropharynx Streptococcus viridians, Streptococcus pneumoniae, Beta-haemolytic streptococci, coagulase-
negative Staphylococci, Veillonella spp., Fusobacterium spp.,  Treponema spp.,
Porphyromonas spp., Prevotella spp., Neisseria spp. and Branhamella catarrhalis, Candida
spp., Haemophilus spp., Diphtheroids, Actinomyces spp., Staphylococcus aureus, Eikenella
corrodens
Stomach Streptococcus, Staphylococcus, Lactobacillus, Peptostreptococcus
Small intestines Lactobacillus spp., Bacteroides spp., Clostridium spp., Mycobacterium spp., Enterococci,
bacteria of Enterobacteriaceae,
Large intestines Bacteroides  spp., Fusobacterium spp., Clostridium spp., Peptostreptococcus spp.,
Escherichia coli, Klebsiella spp.,  Proteus spp., Lactobacillus spp., Enterococci,
Streptococcus spp., Pseudomonas spp., Acinetobacter spp., coagulase-negative
Staphylococci Staphylococcus aureus, Mycobacterium  spp.,  Actinomyces  spp.,
Bifidobacterium bifidum, Enterobacter spp., Peptococcus spp., Methanogens (Archaea),
Salmonella spp.
GIT - Gastro intestinal tract
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of cultures10. These studies show that many DNA
sequences correspond to previously undescribed
microorganisms, and also that every individual has unique
strains of bacteria11,12. Molecular procedures have
shown that aerobes, including Escherichia coli ,
Enterococci and Lactobacilli achieve very high
densities and metabolic activity in the human caecum13.
Use of animals bred under germ free conditions1 4
suggests that gut microflora have a number of important
functions in the body.
Protective functions: Resident bacteria are a crucial
line of defence to colonization by exogenous microbes
and, therefore, are important in prevention of invasion
of tissues by pathogens. Germ free animals are very
susceptible to infection15,16. This is also relevant to
opportunistic bacteria that are present in the gut but have
restricted growth. The equilibrium between species of
resident bacteria provides stability in the microbial
population within the same individual under normal
conditions. However, use of antibiotics can disrupt the
ecological balance and allow overgrowth of species with
potential pathogenicity17. Several mechanisms have been
implicated in the barrier effect, for example, competition
for attachment sites on intestinal epithelial cells and for
nutrient availability18-19. These bacteria can inhibit the
growth of their competitors by producing antimicrobial
substances known as bacteriocins20-21.
Role as probiotics and prebiotics: Probiotic is a
bacterium that provides specific health benefits when
consumed as a food component or supplement. They
are living microorganisms that upon ingestion in specific
numbers, exert health benefits beyond those of inherent
basic nutrition22. According to this definition, probiotics
do not necessarily colonize the human intestine. The
effect of a bacterium is strain specific and cannot be
extrapolated even to other strains of the same species.
The prebiotics are non-digestible food ingredients that
benefit the host by selectively stimulating growth, or
activity, or both, of one or a restricted number of bacteria
in the colon23.
Orally administered probiotics can enhance specific
IgA responses to rotavirus in infected children24 or to
Salmonella Typhi in adults undergoing vaccination with
an attenuated strain25. In healthy people, two different
probiotics administered in a fermented milk product
transiently colonized the gut and enhanced phagocytic
activity of circulating leucocytes for a few weeks while
colonization persisted26. Probiotics and prebiotics have
been shown to prevent colon cancer in several animals,
but their role in reduction of risk of colon cancer in human
beings is not established27. However, probiotics have been
shown to reduce the faecal activity of enzymes known
to produce genotoxic compounds that act as tumour
initiators in human beings28.
Current clinical and animal model studies29 support a
role for certain probiotics, activating the common mucosal
system through the stimulation of gut antigen-presenting
cells to both promote protection and to switch regulatory
mechanisms. It is concluded that a new term is required
to identify bacteria that promote health through driving
mucosal immune mechanisms, compared to those with
strictly local effects. The term immunobiotics has been
suggested as appropriate to fulfil this need29.
Metabolic functions: A major metabolic function of the
gut microflora is fermentation of non-digestible dietary
residue and endogenous mucus produced by the
epithelia 14. Genetic diversity of the microbes provides
various enzymes and biochemical pathways that are
distinct from the host's own constitutive resources. This
results in recovery of metabolic energy and absorbable
substrates for the host, and supply of energy and nutritive
products for bacterial growth and proliferation30-31.
Anaerobic metabolism of peptides and proteins by the
microflora produces short-chain fatty acids and a series
of potentially toxic substances including ammonia,
amines, phenols, thiols, and indols 32 . Colonic
microorganisms also play a part in vitamin synthesis33-34
and in absorption of calcium, magnesium, and iron.
Absorption of ions in the caecum is improved by
carbohydrate fermentation and production of short-chain
fatty acids, especially acetate, propionate, and
butyrate14,35,36. Epithelial cell growth and differentiation
is also affected by gut-microflora. Studies suggest that
intraluminal bacteria affect the proliferation and the
differentiation of epithelial cells in the colon8,37.
The intestinal mucosa is the main interface between
the immune system and the external environment, which
is reflected by the gut-associated lymphoid tissues
containing the largest pool of immunocompetent cells in
the human body38 . Animals bred in a germ free
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environment have low densities of lymphoid cells in the
gut mucosa and circulating concentrations of
immunoglobulins in the blood are low10,39. Microbial
colonization of the gastrointestinal tract affects the
composition of gut associated lymphoid tissue. Many and
diverse interactions between microbes, epithelium and
gut associated lymphoid tissue are involved in modeling
the memory mechanisms of systemic immunity39.The
immune response to microbes relies on innate and
adaptive components, such as immunoglobulin secretion40.
Role of microflora in colon cancer: Intestinal bacteria
can play a part in initiation of colon cancer through
production of carcinogens, cocarcinogens, or
procarcinogens. Some intestinal microbes strongly
increase damage to DNA in colon cells induced by
heterocyclic amines, whereas other intestinal bacteria
can uptake and detoxify such compounds41. Bacteria of
the Bacteroides and Clostridium genera increase the
incidence and growth rate of colonic tumours induced in
animals, whereas other genera such as  Lactobacillus
and Bifidobacteria prevent tumorigenesis42-44. Although
the evidence is not conclusive, colonic flora seem to be
a major environmental factor that modulates risk of
colonic cancer in human beings.
Chromium: Chromium (Cr) is a heavy metal which is
found in the environment commonly in hexavalent (Cr
VI) and trivalent (Cr III) forms. Cr (VI) is a widely
used industrial chemical, extensively used in paints, metal
finishes, steel including stainless steel manufacturing,
alloy cast irons, chrome and wood treatment. The major
non-occupational source of chromium for humans is food
such as vegetables, meat, urban air, and hip or knee
prostheses etc.44,45. Non-occupational exposure to the
metal occurs via the ingestion of chromium containing
food and water, whereas occupational exposure occurs
via inhalation. Cr(III) is poorly absorbed, regardless of
the route of exposure, whereas Cr (VI) is more readily
absorbed46. Animal studies showed that Cr (VI) was
generally more toxic than Cr(III), but neither of the two
states was very toxic by the oral route44,45. Chromium is
localized in the lung, liver, kidney, spleen, adrenals,
plasma, bone marrow, and red blood cells46,47. Cr(VI)
undergoes enzymatic reduction, resulting in the formation
of reactive intermediates and Cr(III)46. The main routes
for the excretion of chromium are via the kidneys/urine
and the bile/feces48. The respiratory and dermal toxicity
of chromium is well documented. Workers exposed to
chromium develop nasal irritation, nasal ulcers,
perforation  of the nasal septum46,47 and hypersensitivity
reactions and "chrome holes" of the skin49,50. Among
the general population, contact dermatitis has been found
to be associated with the use of bleaches and
detergents51. Compounds of both Cr(VI) and Cr(III)
induce developmental defects in experimental animals
including neural tube defects, malformations, and foetal
deaths52,53. The inhalation of chromium compounds has
been shown to be  associated with the development of
cancer in workers in the chromate industry54. There is
evidence for an increased risk of developing nasal,
pharyngeal, and gastrointestinal carcinomas46 due to
cromium exposure.
Cr(III) compounds are also used as micronutrients
and nutritional supplements and have been demonstrated
to exhibit a significant number of health benefits in
animals and humans55. Chromium plays an important role
in glucose and cholesterol metabolism and is thus
essential for man and animals. Chromium is an essential
nutrient required by the human body to promote the action
of insulin in body tissues so that the body can use sugars,
proteins and fats. Chromium polynicotinate, chromium
chloride and chromium picolinate have been used as
nutritional supplement; control blood sugar in diabetes
and may reduce cholesterol and blood pressure levels.
Chromium increases insulin binding to cells, insulin
receptor number and activates insulin receptor kinase
leading to increased insulin sensitivity48,55. It also has
beneficial effect on both muscle strength and body
composition56.
Toxic effects of chromium: Various metals are
responsible for many biochemical, immunological and
physiological essential activities of the body as
micronutrients but some of these can give rise to
disordered functions resulting in increased susceptibility
to infections, a variety of hypersensitivity reactions and
neoplasia. Cr (VI) is highly toxic to all forms of living
organisms and is mutagenic in bacteria 57. Cr (VI) is very
toxic by dermal and inhalation route and causes lung
cancer, nasal irritation, nasal ulcer, hypersensitivity
reactions and contact dermatitis44,45,58. The mechanism
of the Cr (VI)-induced cytotoxicity is not entirely
understood. A series of in vitro and in vivo studies59-61
have demonstrated that Cr (VI) induces an oxidative
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stress through enhanced production of reactive oxygen
species (ROS) leading to genomic DNA damage and
oxidative deterioration of lipids and proteins. A cascade
of cellular events occurs following Cr(VI)-induced
oxidative stress including enhanced production of
superoxide anion and hydroxyl radicals, increased lipid
peroxidation and genomic DNA fragmentation,
modulation of intracellular oxidized states, activation of
protein kinase C, apoptotic cell death and altered gene
expression59-61. Some of the factors in determining the
biological outcome of exposure to chromium include the
bioavailability, solubility of chromium compounds and
chemical speciation, intracellular reduction and interaction
with DNA. The chromium genotoxicity manifests as
several types of DNA lesions, gene mutations and
inhibition of macromolecular synthesis. Further, chromium
exposure may lead to apoptosis, premature terminal
growth arrest or neoplastic transformation. Chromium-
induced tumor suppressor gene p53 and oxidative
processes are some of the major factors that may
determine the cellular outcome. These approaches have
been used to understand the interrelationship between
chromium-induced genotoxicity, apoptosis and effects on
immune response59.
Mechanisms of reduction of Cr (VI) to Cr (III): A
number of mechanisms have been reported by which
Cr (VI) is reduced to Cr (III). In vitro and under
physiological conditions, ascorbic acid, thiols, glutathione,
cysteine, cysteamine, lipoic acid coenzyme A, and
coenzyme M reduce Cr (VI) at a significant rate62.
The in vitro reaction of Cr (VI) with glutathione results
in the formation of a Cr (V) intermediate that is possibly
the form that interacts with cellular macromolecules63.
DT-diaphorase is a major cytosolic enzyme involved in
Cr (VI) reduction64. The NADPH-dependent Cr (VI)
reductase activity of rat liver microsomes has been
attributed to cytochrome P-450, whereas the Cr (VI)
reductase activity of rat liver mitochondria is attributed
to NADH-ubiquinone oxidoreductase (complex I)46 .
Suzuki et al65, showed that the Cr (VI) reductase
reduced Cr (VI) to Cr(III) with at least two reaction
steps via Cr (V) as an intermediate. The mechanisms
of Cr (VI) reduction in the bacteria need further in
depth exploration.
Reduction of Cr (VI) in the body: Chromium enters
the body through inhalation, ingestion and to a lower
extent through absorption via skin. Cr (VI) is poorly
absorbed in the gut, therefore, it is not very toxic when
introduced by oral route. All the ingested Cr (VI) is
reduced to Cr (III) before entering the blood stream.
Cr (III) is unable to enter into the cells but Cr (VI)
enters through membrane anionic transporters. Cr (VI)
is metabolically reduced to Cr (III) in the cell. Cr (VI)
does not react with macromolecules such as DNA,
RNA, proteins and lipids. However, both Cr (III) and
the reductional intermediate Cr (V) are capable of co-
ordinate and covalent interactions with
macromolecules66.
The cells of the immune system form a strong line
of defence against foreign substances. A study was
undertaken67 to investigate the capacity of different
cells of Wistar rats to reduce potentially carcinogenic
hexavalent chromium into less toxic trivalent chromium
in vitro. It was observed that among the single cell
suspensions from the spleen, a peak reduction of 55
per cent was observed with the total spleen cells, 40
per cent with the B-lymphocyte-enriched subpopulation,
10 per cent with T-lymphocytes and 24 per cent with
the macrophages. The reduction by splenic and
peritoneal macrophages was similar. Total thymocytes
reduced 54 per cent of the Cr (VI). Since the most
common route of entry of chromium is through drinking
water and food,  intestinal cells were also investigated.
Among the intestinal cells the maximum reduction of
100 per cent was observed with the upper villus cells
and 72 per cent with the middle villus cells while
reduction was the least (4%) with the crypt cells. The
reduction in the intestinal loop in situ was 100 per cent.
The time taken by each cell type for the peak reduction
of Cr (VI) was markedly different67. The findings thus
showed that the capacity of different cells in the body
differed vastly in their capacity and time taken to reduce
hexavalent chromium. The efficient handling of Cr (VI)
by intestine is due to the presence of a variety of cells
and bacteria. Various organs of the body have capacity
to reduce Cr (VI)66,67.
Reduction of Cr (VI) to Cr (III) by microbes: The
presence of chromate in the environment inhibits most
microorganisms but also promotes the selection of
resistant bacteria 68. Cr (VI) compounds are markedly
efffective than those of Cr (III) due to their high solubility
in water, rapid permeability through biological membranes
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and subsequent interaction with intracellular protein and
nucleic acids. The bacteria present naturally in soil and
water bodies are exposed to Cr through contamination
with industrial effluents, especially from tannery etc. The
processes by which the microorganisms interact with
the toxic metals enabling their removal/and recovery are
biosorption, bioaccumulation and enzymatic reduction.
Microorganisms have evolved resistance mechanism to
select resistant variants to deal with metal toxicity as
the result of exposure to metal contaminated
environments, which cause coincidental selection for
resistant factors for antibiotics and heavy metals.
There are evidences for possible links between heavy
metal and antibiotic resistance in a bacteria because these
traits are generally associated with transmissible plasmids
and the genes are frequently found on the same
plasmid69,70. Bacterial resistance to chromate can be due
to chromosomal mutation or is plasmid-borne71. Many
bacteria belonging to gerera Pseudomonas, Aeromonas,
Enterobacter, Escherichia, Bacillus, Streptomyces,
etc., can reduce Cr (VI) to Cr (III). In each case, the
plasmid bearing strains are approximately 10-fold more
resistant to chromate than the plasmid less strains72 .
Under environmental conditions of metal stress, such
metal and antibiotic resistant population adopts faster by
the spread of R-factors than by mutation and natural
selection thus leading to a very rapid increase in their
numbers73 . Microbial resistance to metal ions and
antibiotics is a potential health hazard.
Some bacteria present in water and soil develop
resistance to chromium on exposure to Cr-containing
effluent in their environment68,74-77. These bacteria
reduce Cr (VI) into Cr (III) and minimize the adverse
effects of Cr (VI) on their growth77. Further, some of
the bacteria bioaccumulate large quantity of Cr and bring
down the residual concentration of Cr (VI) in 24 h78.
Several studies have been done to investigate the effect
of Cr on soil and water bacteria resistant to
chromium57,74-79. In a recent study78, 16 per cent of the
Cr (VI) resistant bacterial strains isolated from tannery
effluent had minimum inhibitory concentration (MIC)
more than 100 mg Cr (VI)/l. Another study80 reports
that under in vitro conditions, Cr-tolerance may depend
on the type of media used, the MIC obtained in the rich
media are from two to five times higher than in minimal
media because heavy metals can be complexed by some
components of media, especially organic substances and
phosphate. Bacterial sensitivity to metal toxicity is known
to depend on their isolation site. In natural bacterial
communities, the development of metal resistance is
greatly enhanced by the horizontal dispersal of genetic
information81. Evolution of resistance via such transfer
between natural bacterial isolates has been shown to
occur in situ and also under laboratory conditions82 .
Widespread bacterial reduction of Cr (VI) to the less
toxic Cr (III) ions is well known79-83. In different bacteria,
chromate reduction is either an aerobic or an anaerobic
process (but not both) and is carried out either by soluble
proteins or by cell membranes81.
The ability of microorganisms to alter their chemical
physiology in order to compensate for potentially traumatic
changes in their external environment represents a built in
factor of safety for biological survival.  Growth of E. coli,
Micrococcus luteus and Azotobactor spp. in the presence
of lead and growth of Chlamydomonas reinhardi in the
presence of mercury are examples of biological
accommodation84-88. Growth stimulation of facultative
Methylobacterium spp. following the addition of
molybdenum or tungsten, which enhances the intracellular
formate dehydrogenase activity, has also been reported89.
Enzymatic reduction of Cr (VI) by hexavalent Cr-tolerant
Pseudomonas ambigua G-1 isolated from activated sludge
has been reported. The intracellular reducing enzyme
required NADH as a hydrogen donor71. A membrane-
associated chromate reductase activity from Enterobacter
cloacae isolated from activated sludge has also been
documented75. In the present context of Cr interaction
with facultative gut bacteria further studies are required
to identify cellular and molecular mechanisms of
accommodation/adaptation as well as stimulation of
growth of Cr-stressed Preudomonas and Lactobacillus
spp. Some bacteria are known to bioaccumulate up to 34
mg Cr/g dry weight78. Intracellular accumulation of such
large amount of Cr may disturb the normal functioning of
the bacterial cell. Several factors including mutagenic
potential of chromium, a Cr (VI) reductional intermediate
product such as Cr (III), a reaction to accumulated Cr or
a selective stimulation of the control of binary fission,
membrane proteins and lipids interaction and other
intracellular mechanisms may play important role. Diverse
mechanisms may be responsible for the development of
resistance for Cr (VI) in microbes, including chromate
efflux85.
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Ingested Cr (VI) and gut microflora: The intestines
have a huge population of bacteria (Table) and the
caecum harbors the largest number of bacteria 90,91.
Thus, bacteria may play an important role in protecting
body from the toxicity of ingested chromium. The
resident bacterial flora of the gastrointestinal tract is
exposed to Cr through ingestion of water and food
contaminated with Cr. It has been reported that human
ingestion of Cr (VI) in drinking water at levels of 1 to
10 ppm is safe due to high capacity of gastrointestinal
tract to reduce Cr (VI) to Cr (III)61-92. In long-term
studies, rats were not adversely affected by 2.4 mg/
kg/day of Cr (VI) as potassium dichromate in drinking
water92. A study was undertaken to investigate the
effects of chronic ingestion of potassium dichromate
[Cr (VI)] on the resident gut microflora of Wistar rats.
A group of rats were kept on drinking water containing
10 ppm Cr (VI) (called Cr-stressed animals) and the
other group was given plain water. After 10 wk
Lactobacillus, Pseudomonas spp. and Esch. coli
were isolated from the caecum of the rats. The most
significant findings of this study were the stimulation
of growth of facultative gut bacteria from the Cr-
stressed rats, and also the significant increase of growth
even in presence of lower concentrations of chromium.
Thus, chromium may act like a prebiotic. Furthermore,
the capacity to reduce Cr (VI) was significantly
decreased along with the increased tolerance of the
bacteria to Cr (higher MIC values), which was
associated with the development of antibiotic resistance.
The effects were most marked with the Pseudomonas
spp. and least with the Esch.  coli. The antibiotic
resistance developed in the Lactobacillus may be a
blessing in disguise as the bacteria may continue to
provide benefits even in patients given antibiotic therapy
(unpublished data). It appeared that the changes were
a sequel to the effort of gut bacteria to provide the first
line of defense to the body by converting toxic Cr (VI)
to a less toxic Cr (III). Our findings further showed
that Pseudomonas obtained from the Cr-stressed rat
had the highest MIC value while the Lactobacillus
and Esch. coli had lower values. As compared to the
bacteria from the normal control rats, the MIC values
were significantly higher in the Cr-stressed rats. This
indicated that bacteria from Cr-stressed animals
tolerated the presence of Cr in the milieu much better.
The stimulated growth of Cr-stressed Pseudomonas
and Lactobacillus, and complete Cr (VI) reduction
capacity (up to 25 mg/l Cr-concentration) indicated their
ability to adaptation. This may also reflect horizontal
genetic transfer resulting from Cr-stress. Diversity of
Cr-resistant and Cr-reducing bacteria in the bacterial
population from a chromium contaminated activated
sludge has been established79. It has also been suggested
that the mechanisms of Cr (VI) resistance and reduction
may differ in microbial community from  group to
group.Therefore, Cr (VI) resistance and reduction
capacity could be the shared abilities and not an
exclusive characteristic of a single group of bacteria.
A number of components in the intestine may be
responsible for the efficient handling of Cr (VI). It has
been reported that bacteria isolated from faeces
sequestrated 3.8±1.7 ug Cr (VI)/109 bacteria; thus the
interesting derivation is that 11-24 mg Cr (VI) can be
eliminated daily with faeces66,68. Further, intestinal
bacteria contain high amounts of Glutathione (GSH)
which efficiently reduces Cr (VI). Enterobacterial
enzymes, such as nitroreductases can also reduce Cr
(VI)93,94. We have also shown that Cr (VI) is efficiently
reduced under in situ intestinal incubation and also by
upper villus and middle villus cells of rat intestine57.
The findings indicate that the gut bacteria have marked
capacity to cope with the increased load of chromium
and may contribute in the protection against chromium
toxicity up to a certain extent. In addition, resistance to
various antibiotics shown by the resident gut bacteria
following chromium ingestion also indicates that use of
chromium as nutritional supplement/micronutrient may
provide significant protection to the gut microflora,
particularly Lactobacillus, against some of the
commonly used antibiotics. The gut is the natural habitat
for a large and dynamic bacterial community. Major
functions of the gut microflora include metabolic
activities that result in salvage of energy and absorbable
nutrients, important trophic effects on intestinal epithelia
and on immune structure and function, and protection
of the colonized host against invasion by alien
microbes78. However, altered functions of resident gut
microflora following chronic exposure of chromium
cannot be ruled out. This, in turn, may adversely affect
the body by depriving it of the benefits provided by the
microflora that may manifest clinically as various
nutritional deficiency syndromes. Thus resident gut
microflora plays a very important role in protection
against metal toxicity.
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Conclusions and future perspectives: Presence of toxic
metals in the environment and their ill effects on body,
including carcinogenicity is known for a long time. The
recent developments have been the understanding of the
capacity of microbes to detoxify and eliminate metals.
Rapid advances have been made in understanding the
biotransformations and the environmental relevance of
metal reduction processes by microbes. Now the
attention is focussed on the role of gut microflora.
However, we still do not know about the precise
mechanisms involved and its overall impact. The genomic
sequences of main metal-reducing microbes are known,
therefore, rapid advances can be expected using the
newer techniques and post-genomic and proteomic
approaches.
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